MedTrace Logo

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

NCT06995573 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.

Conditions

  • Alzheimer Disease

Interventions

DRUG

NSC001

rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor

OTHER

Placebo

matching placebo to NSC001

Sponsors & Collaborators

  • NeuroScios GmbH

    collaborator UNKNOWN

  • NSC-Therapeutics

    lead INDUSTRY

Principal Investigators

  • Manfred Windisch, PhD · NSC-Therapeutics GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-25
Primary Completion
2026-07-30
Completion
2026-09-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06995573 on ClinicalTrials.gov